| 2018 May – 2019 Apr | Principal Investigator. Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis – ECZema TRAlokinumab Trial No. 5 (ECZTRA-5). Leo Pharma. [Clinical Trials] |
| 2017 Dec – 2019 Feb | Principal Investigator. Real-World AR101 Market-Supporting Experience Study Open-Label Extension (RAMSES OLE) (ARC011). Aimmune Therapeutics. [Clinical Trials] |
| 2017 May – 2018 Sep | Principal Investigator. Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (ARC007). Aimmune Therapeutics. [Clinical Trials] |
| 2017 May – 2019 Apr | Principal Investigator. PALISADE Follow-on Study (PALISADE 2) (ARC004). Aimmune Therapeutics. [Clinical Trials] |
| 2016 Jun – 2018 Dec | Principal Investigator. A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients. Novartis. [Clinical Trials] |
| 2016 Sep – 2018 Aug | Principal Investigator. Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency. Green Cross Corporation. [Clinical Trials] |
| 2016 Feb – 2017 Apr | Principal Investigator. Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients. Glaxo Smith Kline. [Clinical Trials] |
| 2016 Aug – 2017 Aug | Principal Investigator. Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema (APeX-1). BioCryst Pharmaceuticals. [Clinical Trials] |
| 2016 Jan – 2017 Sep | Principal Investigator. Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) (ARC003). Aimmune Therapeutics. [Clinical Trials] |
| 2016 Jan – 2018 Jun | Principal Investigator. Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE. Shire. [Clinical Trials] |
| 2015 Dec – 2017 Jul | Principal Investigator. Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy (PEPITES). DBV Technologies. [Clinical Trials] |
| 2015 Oct – 2017 Sep | Principal Investigator. Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis. Stallergenes. [Clinical Trials] |
| 2015 Jan – 2018 Jan | Principal Investigator. Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU. Novartis. [Clinical Trials] |
| 2014 Dec – 2016 May | Principal Investigator. Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE. Shire. [Clinical Trials] |
| 2014 Jan – 2016 May | Principal Investigator. Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients (OPTIMA). Novartis. [Clinical Trials] |
| 2013 Dec – 2016 Feb | Principal Investigator. A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-Derived C1-Esterase Inhibitor (C1-INH) in the Prophylactic Treatment of Hereditary Angiodema (HAE). CSL-Behring. [Clinical Trials] |
| 2013 Dec – 2015 Jan | Lead Canadian Investigator. Assessment of the Economic and Humanistic Burden of Chronic Spontaneous/Idiopathic Urticaria Patients. RTI Health Solutions |
| 2013 Oct – 2015 Dec | Principal Investigator. MA Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quilizumab in Patients with Refractory Chronic Spontaneous Urticaria (CSU). Genentech Inc. [Clinical Trials] |
| 2013 May – 2015 Apr | Principal Investigator. A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma. Merck & Co. Inc. [Clinical Trials] |
| 2014 Jul – 2016 Oct | Principal Investigator. Open-Label Follow-Up Study of the VIPES Study to Evaluate the Long-Term Efficacy and Safety Of the Viaskin Peanut (OLFUS-VIPES Study). DBV Technologies. [Clinical Trials] |
| 2012 Jul – 2014 | Principal Investigator. A Canadian, 12 month, multicenter, open-label study evaluating the oral corticosteroid sparing effect of Xolair (omalizumab) therapy in inadequately-controlled moderate to severe allergic asthma patients (ASTERIX). Novartis. [Clinical Trials] |
| 2012 Jul – 2014 Jan | Principal Investigator. A double-blind, placebo-controlled, randomized trial to study the Viaskin peanut’s efficacy and safety for treating peanut allergy in children and adults (Vipes Study). DBV. [Clinical Trials] |
| 2012 Jul – 2013 | Principal Investigator. A double-blind, randomized, placebo-controlled, multicenter, crossover study of MK-1029 in adult subjects with persistent asthma who remain uncontrolled while being maintained on Montelukast. Merck & Co. Inc. [Clinical Trials] |
| 2012 Jul – 2013 | Principal Investigator. An open-label, single-arm, historically controlled, prospective, multicenter phase III study to evaluate the safety, efficacy and pharmacokinetics of immune globulin intravenous (human) IVIG-SN in subjects with primary immunodeficiency. Green Cross Corporation. [Clinical Trials] |
| 2011 Jul – 2012 | Principal Investigator. A randomized, double-blind, placebo-controlled, dose ranging Phase II study to assess the efficacy and safety of 100 IR, 300 IR, and 500 IR sublingual tablets of House Dust Mite allergen for the treatment of allergic rhinitis in an Environmental Exposure Chamber model. Stallergenes S.A. [Clinical Trials] |
| 2011 Jul – 2012 Jul | Principal Investigator. A multicenter, double-blind, randomize, placebo-controlled, parallel-group study evaluating the efficacy and safety of grass (Phleum pretense) sublingual tablet (SCH 697243) in subjects between 5 and 65 years of age, with a history of grass pollen-induced rhinoconjunctivitis, with or without asthma. Schering-Plough Research. [Clinical Trials] |
| 2011 Jul – 2012 Jun | Principal Investigator. A 12 week, randomized, double-blind, placebo-controlled, parallel-group study assessing efficacy and safety of BI 54903 administered as 90.9 µg twice daily or 181.9 µg once daily pm via Respimat® B inhaler in patients with asthma inadequately controlled with SABA alone. BoehringerIngelheim. [Clinical Trials] |
| 2011 Jul – 2012 Jun | Principal Investigator. A 12 week, randomized, double-blind, placebo-controlled, parallel-group study assessing efficacy and safety of BI 54903 administered as 181.9 µg twice daily or 363.6 µg once daily pm via Respimat® B inhaler in patients with asthma inadequately controlled with SABA alone. BoehringerIngelheim. [Clinical Trials] |
| 2010 Jul – 2012 Jun | Principal Investigator. A prospective, randomized, case controlled, pilot study to evaluate the effect of Ketotifen on the adverse events associated with peanut desensitization in children with peanut allergies. Mast Cell Pharmaceuticals Inc. [Clinical Trials] |
| 2009 Jul – 2011 Jun | Principal Investigator. A multi-center, double blind, randomized, placebo controlled, parallel group study evaluating the efficacy and long-term safety of ragweed (Ambrosia artemisiifolia) sublingual tablet (SCH 39641) in adult subjects with a history of ragweed-induced rhinoconjunctivitis with or without asthma. Schering-Plough Research. [Clinical Trials] |
| 2008 Jul – 2010 | Principal Investigator. A multi-center, double blind, randomized, placebo controlled, parallel group study evaluating the efficacy and safety of grass (phleum pretense) sublingual tablet (SCH 697243) in adult subjects with a history of grass pollen induced rhinoconjunctivitis with or without asthma. Schering-Plough Research. [Clinical Trials] |
| 2008 Jul – 2009 | Principal Investigator. XCEED: Xolair Canadian Evaluation of Effectiveness in Asthmatic Disease: A post-registration evaluation of long-term Xolair therapy on patient relevant outcomes, medical resource use and asthma medication requirements, in a prospective cohort of asthma patients treated under real world medical practice conditions. Xolair. [Clinical Trials] |
| 2008 Jul – 2009 Jun | Principal Investigator. A Double-blind, randomized, placebo-controlled study to evaluate the efficacy of Cat-PAD in Cat Allergic subjects following challenge to Fel-d-1 in an environmental exposure chamber. Allied/Cetero Research. [Clinical Trials] |
| 2008 Jul – 2009 Jun | Principal Investigator. A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of DX-88 (Ecallantide) for the treatment of acute attacks of hereditary angioedema. Dyax Corporation (Cambridge, MA). [Clinical Trials] |
| 2007 Jul – 2008 Jun | Principal Investigator. A Clinical study of the pharmacokinetics, efficacy and safety of immune globulin intravenous (human) Omr-IgG-am IGIV in subjects with primary immune deficiency diseases. Allphase Clinical Research. [Clinical Trials] |
| 2007 Jul – 2008 Jun | Principal Investigator. A 26 week placebo-controlled, efficacy and safety study of mometasonefuroate/formoterol fumarate combination formulation compared with mometasonefuroate and formoterol monotherapy in subjects with persistent asthma previously treated with medium-dose inhaled glucocorticosteroids. Schering-Plough Research. [Clinical Trials] |
| 2007 | Principal Investigator. Efficacy and safety/tolerability of ragweed MATA MPL, a randomized, placebo-controlled, double-blind study. Allied Research International Inc. (ON). [Clinical Trials] |
| 2007 | Principal Investigator. A randomized, placebo-controlled, double-blind Phase II study of the safety and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. Pharming. [Clinical Trials] |
| 2007 | Principal Investigator. A randomized, double blind, placebo controlled, multi-national, multi-centre, Phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis. Stallergens. [Clinical Trials] |
| 2007 | Principal Investigator. Xolair Canadian Evaluation of Effectiveness in Asthmatic Disease. Novartis Pharmaceuticals Corporation. [Clinical Trials] |
| 2006 Jul – 2008 Jun | Principal Investigator. Human pasteurized C1 esterase inhibitor concentrate in subjects with congenital c1-INH deficiency and acute abdominal, facial and laryngeal HAE attacks. CSL Behring AG. [Clinical Trials] |
| 2006 | Principal Investigator. Double-blind, randomized, placebo-controlled, parallel group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for intermittent allergic rhinitis (IAR). Schering-Plough Research. [Clinical Trials] |
| 2006 | Principal Investigator. Double-blind, randomized, placebo-controlled, parallel group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER). Schering-Plough Research. [Clinical Trials] |
| 2006 | Principal Investigator. A post-registration evaluation of long term Xolair (omalizumab) therapy on patient-relevant outcomes, medical resource use and asthma medication requirements, in a prospective cohort of asthma patients treated under real world medical practice conditions. Novartis Pharma Canada Inc. [Clinical Trials] |
| 2005 | Principal Investigator. An Open-Label, Multi-centre, randomized, parallel clinical effectiveness study to determine the level of asthma control in adolescent and adult patients treated with Advair versus Usual Care for 24 weeks. GlaxoSmithKline. [Clinical Trials] |
| 2004 Jul – 2007 Jun | Principal Investigator. A Phase II Randomized Double Blind, Placebo Controlled, Oral food challenge Trial of Xolair in Peanut Allergy. GenetechLtée (Can). [Clinical Trials] |
| 2004 Jul – 2007 Jun | Principal Investigator. The Treatment of Hereditary Angioedema with a Purified A1 Esterase Inhibitor Concentrate. Pharming Inc. [Clinical Trials] |
| 2004 Jul – 2005 Jun | Principal Investigator. A comparative double-blind, double-dummy study of desloratadine (DL) 5mg once daily, Cetirizine 10mg once daily, and placebo once daily in patients with Chronic Idiopathic urticaria (CIU). Schering Canada Inc. [Clinical Trials] |
| 2004 Jul – 2005 Jun | Principal Investigator. Ciclesonide Nasal Spray in the Treatment of Paediatric Perennial Allergic Rhinitis (PAR). Atlana. [Clinical Trials] |
| 2004 | Principal Investigator. The Allergenicity of Natural Rubber Latex Gloves. Malaysian Rubber Board. [Clinical Trials] |
| 2003 Jul – 2007 Jun | Principal Investigator. The Role of Fungal Infections and Allergy in Patients with Chronic Sinusitis. [Clinical Trials]
In collaboration with Dr. Don Beezhold. |
| 2003 Jul – 2004 | Jun Principal Investigator. A Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Clinical trial to assess the Safety and Efficacy of Cyclesonide ( 200 mcg once daily) Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis in Patients 12 years and Older. [Clinical Trials] |
| 2003 – 2004 | Principal Investigator. A 12 week, randomized, double-blind, placebo-controlled, parallel-group study assessing efficacy and safety of BI 54903 administered as 181.9 µg twice daily or 363.6 µg once daily pm via Respimat® B inhaler in patients with asthma inadequately controlled with SABA alone. [Clinical Trials] |
| 2003 – 2004 | Principal Investigator. IGIV-C Rapid Infusion Trial in Primary Immune Deficient Patients. Study # 100348. [Clinical Trials] |
| 2002 – 2003 | Collaborator. A phase III, 28 week, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of subcutaneous omalizumab in adult and adolescent patients with severe persistent allergic asthma who remain inadequately controlled despite GINA (2002) step 4 therapy. [Clinical Trials] |
| 2002 – 2003 | Principal Investigator. A Double Blind Randomized Placebo Controlled Parallel Group Dose Ranging Study Assessing the Efficacy and Safety of Grass Pollen Allergen Tablets Once a Day in Adult Subjects with Seasonal Grass Pollen Allergic Rhinoconjunctivitis. [Clinical Trials] |
| 2002 | Collaborator. Double-Blind, Placebo- Controlled Study of the Effect of Desloratidine in Subjects with Perennial Allergic Rhinits. [Clinical Trials] |
| 2001 Jul – 2002 Jun | Collaborator. Double-Blind, Placebo- Controlled Study of the Effect of sublingual ragweed immunotherapy in seasonal allergic Rhinitis. [Clinical Trials] |
| 2000 | Principal Investigator. A Randomized Double-Blind Parallel Group Trial Comparing the Safety and Efficacy of IVIG Chromatography 10% (Experimental) with IVIG Solvent Detergent Treated 10% (Control) in Patients with Primary Immune Deficiency (PID). [Clinical Trials] |
| 1999 Jul – 2000 Jun | Collaborator. Efficacy and Safety of SCH 034117 in the Treatment of Chronic Idiopathic urticaria. [Clinical Trials] |
| 1999 | Collaborator. Efficacy and Safety of SCH 34117 Compared to Cetirizine in the Treatment of Patients with Seasonal Allergic Rhinitis. [Clinical Trials] |
| 1999 | Collaborator. A Double-Blind Randomized Parallel Study Comparing the Efficacy and Safety of Fexofenidine HCI 120mg QD, 180mg QD, Cetirizine HCI 10mg QD, and Placebo QD in the Treatment of Perennial Allergic Rhinitis. [Clinical Trials] |
| 1998 Jul – 2001 Jun | Co-Principal Investigator. Allergenicity of Recombinant Latex Allergens and Mutagenesis. [Clinical Trials] |
| 1998 Jul – 2001 Jun | Co-Principal Investigator. Characterization of IgE epitopes of natural rubber latex allergens. [Clinical Trials] |
| 1998 | Principal Investigator. Latex Allergy in Operating Room Nurses. [Clinical Trials] |
| 1997 – 1998 | Co-Principal Investigator. Cloning and characterization of latex protein allergens. [Clinical Trials] |
| 1996 Jul – 1997 Jun | Collaborator. A Multicenter, Double-blind, Randomized, Placebo-Controlled, Parallel Study Comparing the Efficacy and Safety of Four Dosage Strengths of Fexofenadine HCI (20, 60, 120 & 24mg BID) in the Treatment of Chronic Idiopathic urticaria. [Clinical Trials] |
| 1996 – 1998 | Founder. Resident Educational Grant. Glaxo Wellcome Inc. [Grants]
For Canadian Society of Allergy and Clinical Immunology– Annual grant to train Canadian clinical immunology and allergy residents – $50,000-60,000. |
| 1996 | Resident grant for Canadian trainees in Clinical Immunology and Allergy travel and textbook funding. Schering Canada Inc. [Grants] |
| 1996 | Principal Investigator. Cyclosporine in the treatment of refractory chronic idiopathic urticaria. Sandoz Canada Inc. [Clinical Trials] |
| 1996 | Principal Investigator. Comparative study of the Safety and Efficacy of the twice daily Fexofenadine HCI 120mg combination versus its component alone in the management of Ragweed Seasonal Allergy. Hoechst Marion Roussel. [Clinical Trials] |
| 1996 | Collaborator. Comparison of Fexofenadine versus Loratadine in Seasonal Allergic Rhinitis. Hoechst Marion Roussel. [Clinical Trials] |
| 1996 | Co-Principal Investigator. Identification of specific IgE antibody to latex allergic components and extracts of latex urinary catheters. C.R. Bard. [Clinical Trials] |
| 1996 | Principal Investigator. Report of Tolerability of Biogel Nebula Non-Latex Gloves in Patients with Type 1 and Type 4 Hypersensitivity. London International. [Clinical Trials] |
| 1995 Jul – 1997 Jun | Collaborator. The Acquisition of a State of Tolerance in Peanut Allergic Individuals. A Trial of Rush Desensitization to Peanut Following Controlled Mast Cell Degranulation by Compound 48/80, in collaboration with Dr. Peter Vadas. [Clinical Trials] |
| 1995 Jul – 1996 Jun | Co-Principal Investigator. Skin test determination and measurement of latex allergen levels in medical products (gloves, masks). 3M Health Care, Alladin Corp. [Clinical Trials] |
| 1995 – 1998 | Principal Investigator. Epidemiologic Studies on sensitization to latex at two Hamilton Hospitals. [Clinical Trials] |
| 1995 | Collaborator. Allervax Ragweed, A Study of the Safety and Efficacy of Allervax Ragweed for Treatment of Allergy Symptoms Induced by Natural Exposure to Ragweed Pollen Season. Hoechst Marion Roussel. [Clinical Trials] |
| 1995 | Collaborator. A Double-Blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Fexofenadine 60mg BID, 120mg QD and Placebo in the Treatment of Perennial Allergic Rhinitis. Hoechst Marion Roussel. [Clinical Trials] |
| 1994 Jul – 1996 Jun | Co-Principal Investigator. Characterization and quantification of latex protein allergens. Regent. [Clinical Trials] |
| 1994 | Collaborator. Six Month Safety Study of MometasoneFuroate Aqueous Nasal Spray in Perennial Rhinitis Patients. Schering Canada Inc. [Clinical Trials] |
| 1994 | Collaborator. Efficacy and Safety of MometasoneFuroate Aqueous Nasal Spray vs. Placebo and Flonase in Treatment of Seasonal Allergic Rhinitis Patients. Schering Canada Inc. [Clinical Trials] |
| 1994 | Collaborator. Efficacy and Safety of MometasoneFuroate Aqueous Nasal Spray vs. Beconase AQ and Placebo in Treatment of Perennial Rhinitis. Schering Canada Inc. [Clinical Trials] |
| 1994 | Co-Principal Investigator. Occupational Asthma from Natural Rubber Latex Glove Powder. Ontario Allergy Society. [Grants] |
| 1993 | Collaborator. Double-blind, Placebo-Controlled Study of Intranasal FluticisonePropronate vs. Beclomethasone Dipropionate in the Treatment of Adults with Perennial Allergic Rhinitis. Glaxo Canada. [Clinical Trials] |
| 1992 | Co-Principal Investigator. The Effect of the H2 Antagonist Cimetidine on the Pharmacokinetics and Pharmacodynamics of the H1 Antagonist Hydroxyzine in Patients with Chronic urticaria. University of Manitoba. [Grants] |
| 1992 | Co-Principal Investigator. Double-blind, Double-dummy Placebo Controlled Group Comparative Study on the Efficacy of Tipredane Nasal Spray at Doses 800mg and 1600mg/day in Patients with Seasonal Ragweed Pollen Allergic Rhinitis. Fisons Pharmaceuticals (North York, ON). [Clinical Trials] |
| 1990 Jul – 1991 Jun | Co-Principal Investigator. Double-blind Controlled Trial of Zaditen vs. Atarax in the Treatment of Chronic Idiopathic urticaria. Sandoz Canada Inc. [Clinical Trials] |
| 1989 Jul – 1990 Jun | Co-Principal Investigator. Double-blind Clinical Trial of Zaditen vs. Placebo in Chronic Idiopathic urticaria. Sandoz Canada Inc. [Clinical Trials] |
| 1989 | Collaborator. Comparative Study on the Onset of Action and Potency of Cetirizine (10mg) vs. Astemizole (10mg) in the Treatment of Seasonal Allergic Rhinitis. Pfizer Canada Inc. [Clinical Trials] |
| 1988 Jul – 1990 Jun | Principal Investigator. A Double-blind Randomized, Placebo Controlled Parallel Study Comparing the Safety and Efficacy of Terfenadine 120mg or Hydroxyzine 100mg for 12 weeks in the Treatment of Chronic Idiopathic urticaria. Merrill-Dow. [Clinical Trials] |
| 1988 | Collaborator. Double-blind Comparative Study of Nodocromil Sodium and Placebo in the Treatment of Perennial Allergic Rhinitis. Fisons Pharmaceuticals (North York, ON). [Clinical Trials] |
| 1987 | Principal Investigator. Double-blind Study of the Efficacy and Safety of Cetirizine, Terfenadine and Placebo in the Treatment of Chronic Idiopathic urticaria. Pfizer Canada Inc. [Clinical Trials] |
| 1985 | Collaborator. Clinical Trial in the Treatment of Perennial Rhinitis with Astemizole. Janssen Pharmaceutica Inc. [Clinical Trials] |
| 1985 | Collaborator. Clinical Trial of Seasonal Allergic Rhinitis with Astemizole. Janssen Pharmaceutica Inc. [Clinical Trials] |
| 1983 Jul – 1984 Jun | Principal Investigator. Controlled Trial of H1 Antagonists in the Treatment of Chronic Idiopathic urticaria. Janssen Pharmaceutica Inc. [Clinical Trials] |
